minoxidil has been researched along with Genetic Predisposition in 6 studies
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials." | 4.86 | Male androgenetic alopecia. ( Rathnayake, D; Sinclair, R, 2010) |
| "Its physiopathology comprises a genetic predisposition affording an exacerbated response of the hair follicles cells to androgens aggravated by scalp inflammation and extrinsic factors." | 2.61 | Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. ( Beck, R; da Silva, C; Katzer, T; Leite Junior, A, 2019) |
| "The exact pathogenesis of androgenetic alopecia is not well understood." | 2.49 | Pattern hair loss in men: diagnosis and medical treatment. ( Banka, N; Bunagan, MJ; Shapiro, J, 2013) |
| "Dutasteride has been shown to be more effective than finasteride in the treatment of AGA but is not yet a recommended therapy." | 2.45 | Androgens and hair loss. ( Alsantali, A; Shapiro, J, 2009) |
| "In advanced cases, men may develop baldness with remaining hair exclusively in the temporal and occipital regions." | 2.42 | [Androgenetic alopecia. Current aspects of a common phenotype]. ( Hanneken, S; Kruse, R; Nöthen, MM; Ritzmann, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katzer, T | 1 |
| Leite Junior, A | 1 |
| Beck, R | 1 |
| da Silva, C | 1 |
| Emre, S | 1 |
| Metin, A | 1 |
| Caykoylu, A | 1 |
| Akoglu, G | 1 |
| Ceylan, GG | 1 |
| Oztekin, A | 1 |
| Col, ES | 1 |
| Alsantali, A | 1 |
| Shapiro, J | 2 |
| Rathnayake, D | 1 |
| Sinclair, R | 1 |
| Banka, N | 1 |
| Bunagan, MJ | 1 |
| Hanneken, S | 1 |
| Ritzmann, S | 1 |
| Nöthen, MM | 1 |
| Kruse, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.[NCT02548689] | 10 participants (Actual) | Observational | 2015-07-31 | Terminated (stopped due to Original lead investigator left Northwestern University) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for minoxidil and Genetic Predisposition
| Article | Year |
|---|---|
Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens.
Topics: Adult; Alopecia; Androgen Antagonists; Finasteride; Genetic Predisposition to Disease; Hair; Humans; | 2019 |
Androgens and hair loss.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alop | 2009 |
Male androgenetic alopecia.
Topics: Administration, Oral; Administration, Topical; Alopecia; Androgen Receptor Antagonists; Azasteroids; | 2010 |
Pattern hair loss in men: diagnosis and medical treatment.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Azasteroids; Dutasteride; Female; Finasteride; Ge | 2013 |
[Androgenetic alopecia. Current aspects of a common phenotype].
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Disease Progression; Enzyme Inhibitors; Female; | 2003 |
1 other study available for minoxidil and Genetic Predisposition
| Article | Year |
|---|---|
Clinical characteristics and HLA alleles of a family with simultaneously occurring alopecia areata.
Topics: Adrenal Cortex Hormones; Adult; Alopecia Areata; Anxiety; Child; Compulsive Personality Disorder; Cr | 2016 |